Blood speaks: Personalised medicine profiling for heart failure patients

Affiliations

¹ SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States.
² SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States. Electronic address: heartman4ever@icloud.com.

Comment

Fareheh Firouzi et al. EBioMedicine. 2020 Aug.

. 2020 Aug:58:102900.

doi: 10.1016/j.ebiom.2020.102900. Epub 2020 Jul 22.

¹ SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States.
² SDSU Heart Institute and Department of Biology, San Diego State University, San Diego, CA, United States. Electronic address: heartman4ever@icloud.com.

No abstract available

Conflict of interest statement

Declaration of Competing Interest F. Firouzi has nothing to disclose. M.A. Sussman has nothing to disclose.

Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3.
Wolfien M, Klatt D, Salybekov AA, Ii M, Komatsu-Horii M, Gaebel R, Philippou-Massier J, Schrinner E, Akimaru H, Akimaru E, David R, Garbade J, Gummert J, Haverich A, Hennig H, Iwasaki H, Kaminski A, Kawamoto A, Klopsch C, Kowallick JT, Krebs S, Nesteruk J, Reichenspurner H, Ritter C, Stamm C, Tani-Yokoyama A, Blum H, Wolkenhauer O, Schambach A, Asahara T, Steinhoff G. Wolfien M, et al. EBioMedicine. 2020 Jul;57:102862. doi: 10.1016/j.ebiom.2020.102862. Epub 2020 Jul 4. EBioMedicine. 2020. PMID: 32629392 Free PMC article. Clinical Trial.

1. Wolfien M., Klatt D., Salybekov A.A. Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype / phenotype analysis of post-MI myocardial regeneration response induced by CABG / CD133 + bone marrow hematopoietic stem cell treatment in RCT PERFEC. EBioMedicine. 2020 doi: 10.1016/j.ebiom.2020.102862. - DOI - PMC - PubMed
1. Noiseux N., Mansour S., Weisel R. The IMPACT-CABG trial: a multicenter, randomized clinical trial of CD133+ stem cell therapy during coronary artery bypass grafting for ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2016;152:1582–1588. Mosby Inc. - PubMed
1. Steinhoff G., Nesteruk J., Wolfien M. Cardiac function improvement and bone marrow response-outcome analysis of the randomized PERFECT phase III clinical trial of intramyocardial CD133 + application after myocardial infarction the PERFECT trial investigators group. EBioMedicine. 2017;22:208–224. - PMC - PubMed
1. Hassan Naseri M., Madani H., Hossein Ahmadi Tafti S., et al. COMPARE CPM-RMI Trial: intramyocardial transplantation of autologous bone marrow-derived CD133 + Cells and MNCs during CABG in patients with recent MI: a phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. Cell Jn.d. 2018;20:267–77. - PMC - PubMed
1. Ayyat K.S., Argawi A., Mende M. Combined coronary artery bypass surgery with bone marrow stem cell transplantation: are we there yet? Ann Thorac Surg. 2019;108:1913–1921. - PubMed